Allegro Ophthalmics Announces Positive Results of Ex-U.S. Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/ASCRS?src=hash" target="_blank"gt;#ASCRSlt;/agt;--Allegro announces positive results of ex-US proof-of-concept clinical trial of new investigational ALG-1007 topical drop for dry eye disease.

Full Story →